Harvest Portfolios Group Inc. Has $56.89 Million Stock Holdings in AstraZeneca PLC $AZN

Harvest Portfolios Group Inc. reduced its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 814,163 shares of the company’s stock after selling 9,798 shares during the quarter. AstraZeneca makes up about 1.3% of Harvest Portfolios Group Inc.’s portfolio, making the stock its 24th largest holding. Harvest Portfolios Group Inc.’s holdings in AstraZeneca were worth $56,894,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of AZN. Lindbrook Capital LLC increased its holdings in AstraZeneca by 1.9% in the first quarter. Lindbrook Capital LLC now owns 7,574 shares of the company’s stock valued at $557,000 after purchasing an additional 141 shares during the period. Principal Securities Inc. grew its position in shares of AstraZeneca by 0.5% in the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company’s stock valued at $2,062,000 after buying an additional 142 shares during the last quarter. Sage Mountain Advisors LLC increased its stake in shares of AstraZeneca by 3.4% in the first quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company’s stock valued at $329,000 after buying an additional 147 shares during the period. Pekin Hardy Strauss Inc. raised its position in shares of AstraZeneca by 4.2% during the second quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock worth $255,000 after acquiring an additional 148 shares during the last quarter. Finally, Richardson Financial Services Inc. lifted its stake in shares of AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after acquiring an additional 149 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a report on Monday, October 27th. They set a “buy” rating for the company. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Price Performance

AZN stock opened at $83.77 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The company’s 50-day moving average is $81.31 and its 200-day moving average is $75.38. The stock has a market capitalization of $259.80 billion, a PE ratio of 31.49, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $86.57.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. During the same period in the prior year, the business earned $2.08 EPS. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. Equities research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.